Single clone antibody of antimutagen hepatitis B virus surface antigen

A hepatitis B virus, monoclonal antibody technology, applied in antiviral immunoglobulin, cells modified by introducing foreign genetic material, fusion cells, etc. Treatment and other issues to achieve the effect of ensuring the quality of blood

Inactive Publication Date: 2005-10-12
徐钧
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, these diagnostic reagents have a fatal flaw, that is, they cannot detect the mutated hepatitis B virus, especially the hepatitis B virus with a mutated surface antigen HBsAg, which cannot be diagnosed with conventional reagents, which will cause missed diagnosis.
So that hepatitis B virus carriers or hepatitis B patients can not be diagnosed, so they can not get treatment
What's more serious is that when screening blood donors, if routine kits are used, blood from hepatitis B patients may be transfused to recipients as healthy blood, resulting in serious cross-infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment one: the monoclonal antibody of anti-hepatitis B virus surface antigen (HBsAg) is prepared by hybridoma technology

[0021] 1. Materials

[0022] BALB / C pure line mice, female, 8 weeks old. SP2 / 0 myeloma cell line, RPMI1640 medium, newborn calf serum, hypoxanthine-methotrexate-thymine (HAT), hypoxanthine-thymine (HT), polyethylene glycol (PEG4000), (all of the above Courtesy of Huamei Bioengineering Corporation). Horseradish peroxidase (HRP)-labeled goat anti-mouse immunoglobulin (Wuhan Boster Biological Products Company).

[0023] 2. Method

[0024] 1. Immunogen preparation 10 μg (5 μl, 2 μg / μl) antigen was dropped on a 2 mm×2 mm nitrocellulose membrane (NC), and dried in the air.

[0025] 2. Immunization was implanted in the spleen, the mouse was anesthetized with ketamine, the spleen area was plucked after the limbs were fixed, alcohol was disinfected, a 5 mm incision was made below the costal edge of the left midaxillary line, the lower edge of the sp...

Embodiment 2

[0035] Example 2: Anti-HBsAg monoclonal antibody detects variant surface antigen

[0036] 1. Construction and expression of recombinant plasmids expressing variant surface antigens

[0037] A pair of primers were designed for two tests of the HBV S gene, and 21 pairs of site-specific mutation primers were designed according to the mutation sites of the S gene reported in the literature, and the HBV S gene was site-directedly mutated by PCR. The mutated S gene was cloned into the eukaryotic expression vector PCR3.1, and it was used in the experiment after being confirmed by sequencing. A total of 21 recombinant plasmids expressing variant HBsAg were constructed.

[0038] 21 recombinant plasmids expressing variant HBsAg were transfected into COS-7 cells, and the supernatant was collected.

[0039] 2. Detection of reactivity of anti-HBsAg monoclonal antibody E1C with variant surface antigen

[0040] Coat the purified anti-HBs monoclonal antibody E1C with an appropriate dilution ...

Embodiment 1

[0045] The identification result of embodiment 1 and embodiment 2 is as follows:

[0046] 1. The establishment and cloning of hybridoma cell lines and the ELISA titer of immunized mouse blood reached 1:10 4 As above, the splenocytes were fused with SP2 / 0 cells and cultured in HAT medium. Cell clonal growth was seen in some wells about 1 week later. After 2 weeks, the cells grew to more than 1 / 3 of the bottom area of ​​the well. The success rate of fusion was 75%, and the specificity The positive rate of antibody was 28.3%. One best hybridoma cell line E1C was retained after three times of cloning.

[0047] 2. Identification of anti-mutant HBsAg monoclonal antibody

[0048] 2.1 Titer The monoclonal antibody titers in E1C ascites type monoclonal antibody and cell culture supernatant were detected by indirect ELISA method were 1∶6.4×10 4 , 1:160.

[0049] E 1C

[0050] Note: Positive standard: OD value of detection hole / OD value of control group > 2.1

[0051] 2....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A process of preparing single-colon antibody resisting surface antigen of hepatitis B virus mutant from CGMCCHBSP2. The single-colon antibody can detect 14 types hepatitis B virus containing mutant and wild strain and replace HBsAb in fluorogence diagnostic kit. It can avoid mistake induced by normal agent and be used widely.

Description

technical field [0001] The invention belongs to hepatitis B virus antibody, in particular to a monoclonal antibody against wild and mutated multifunctional hepatitis B virus surface antigens. Background technique [0002] Hepatitis B is a global health problem. There are about 350 million chronic carriers of HBV in the world, and 2 million patients die from hepatitis B every year, making it the ninth leading cause of death in the world. my country's HBV chronic carriers account for 1 / 3 of the world's total, and it is the country with the highest HBV virus carrier rate in the world. The estimated population HBsAg positive rate was 10.3%. There are more than 100 million asymptomatic HBsAg carriers, and more than 30 million people with current symptoms, the incidence rate is about 30.41%. Hepatitis B not only seriously threatens the health of our people, but also brings serious economic burden to the society. [0003] The mutation rate of HBV is relatively high, and some st...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N5/16C12P21/08G01N33/577
Inventor 徐钧解军聂继盛
Owner 徐钧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap